Zura Bio (ZURA) Net Cash Flow (2022 - 2026)
Zura Bio (ZURA) posted quarterly Net Cash Flow of $116.2 million for Q1 2026, up 2059.64% year-over-year from $5.4 million in Q1 2025, and up 492.39% quarter-over-quarter from -$29.6 million in Q4 2025.
Zura Bio (ZURA) Net Cash Flow (2022 - 2026) Analysis & Trends
Zura Bio's Net Cash Flow history runs 5 years deep, the most recent figure standing at $116.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 2059.64% year-over-year to $116.2 million; the TTM figure through Mar 2026 stood at $55.0 million (up 324.58% YoY), while the FY2025 annual figure was -$67.1 million, down 187.48% from the prior year.
- Net Cash Flow for Q1 2026 stood at $116.2 million, up from -$29.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $116.2 million in Q1 2026, with the low at -$29.6 million in Q4 2025.
- The 5-year median for Net Cash Flow is -$4.1 million (2023), against an average of $7.4 million.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow surged 24317.21% in 2023, then sank 6869.82% in 2025.
- Zura Bio's Net Cash Flow stood at -$1.5 million in 2022, then tumbled by 173.48% to -$4.1 million in 2023, then sank by 189.24% to -$11.7 million in 2024, then tumbled by 152.58% to -$29.6 million in 2025, then surged by 492.39% to $116.2 million in 2026.
- Business Quant data shows ZURA's Net Cash Flow at $116.2 million in Q1 2026, -$29.6 million in Q4 2025, and -$15.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Zura Bio | 706.30 Mn | 706.30 Mn | - | -116.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -116.09 Mn |
| Jun 30, 2026 | -116.09 Mn |
| Mar 31, 2026 | 116.19 Mn |
| Mar 31, 2026 | 116.19 Mn |
| Dec 31, 2025 | -29.61 Mn |
| Dec 31, 2025 | -29.61 Mn |
| Sep 30, 2025 | -15.47 Mn |
| Sep 30, 2025 | -15.47 Mn |
| Jun 30, 2025 | -16.08 Mn |
| Jun 30, 2025 | -16.08 Mn |
| Mar 31, 2025 | -5.93 Mn |
| Mar 31, 2025 | -5.93 Mn |
| Dec 31, 2024 | -11.72 Mn |
| Dec 31, 2024 | -11.72 Mn |
| Sep 30, 2024 | -222,000.00 |
| Sep 30, 2024 | -222,000.00 |
| Jun 30, 2024 | -6.63 Mn |
| Jun 30, 2024 | -6.63 Mn |
| Mar 31, 2024 | -9.99 Mn |
| Mar 31, 2024 | -9.99 Mn |